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Background: Patients with Type 2 Diabetes Mellitus (T2DM) are increasingly using complementary and alternative
medicine (CAM) therapies due to difficulty in adhering to the therapeutic regimens and lifestyle changes
necessary for disease management. Little is known about the prevalence and mode of CAM use among patients
with T2DM in Lebanon.
Objective: To assess the prevalence and modes of CAM use among patients with T2DM residing in Beirut, Lebanon.
Methods: A cross-sectional survey of T2DM patients was conducted on patients recruited from two major referral centers
in Beirut- a public hospital and a private academic medical center. In a face-to-face interview, participants completed a
questionnaire comprised of three sections: socio-demographic, diabetes characteristics and types and modes of CAM use.
Descriptive statistics, univariate and multivariate logistic regression analyses were utilized to assess the prevalence and
correlates of CAM use, as well as whether the use was complementary or alternative to mainstream medicine. The main
outcome in this study, CAM use, was defined as using CAM at least once since diagnosis with T2DM.
Results: A total of 333 T2DM patients completed the survey (response rate: 94.6%). Prevalence of CAM use since
diagnosis with the disease was 38%. After adjustment, CAM use was significantly associated with a “married” status, a
longer duration of T2DM, the presence of disease complications, and a positive family history of the disease. Folk foods
and herbs were the most commonly used CAM followed by natural health products. One in five patients used CAM as
alternative to conventional treatment. Only 7% of CAM users disclosed the CAM use to their treating physician. Health
care practitioners were the least cited (7%) as influencing the choice of CAM among users.
Conclusion: The use of CAM therapies among T2DM patients in Lebanon is prevalent. Decision makers and care
providers must fully understand the potential risks and benefits of CAM therapies to appropriately advise their patients.
Attention must be dedicated to educating T2DM patients on the importance of disclosing CAM use to their physicians
especially patients with a family history of diabetes, and those who have had the disease for a long time.
Keywords: Complementary and alternative medicine, Type-two diabetes mellitus, Prevalence, Patient safety, Integration,
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Diabetes is a chronic debilitating medical condition that,
despite recent advances in care and management, still pre-
cipitates substantial morbidity, mortality and long term
complications on patients and their families [1]. The glo-
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the EMR has a diabetes prevalence that is among the high-
est in the world with an estimated 9.2% of the adult popu-
lation having the disease [5]. The prevalence of T2DM
among adults in Lebanon (15.8%) is lower than that re-
ported in many other EMR countries, including Bahrain
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lence of T2DM over time, since this prevalence in the
country has increased by 36% in a five-year period, from
11.6% in 1999 to 15.8% in 2004 [6,8].
Although the use of insulin is considered to be a
quantum leap in the management of diabetes, living with
T2DM remains a challenge requiring considerable dedica-
tion and commitment to a life-long regimen imposed by
this chronic disease [9]. In addition, the achievement of
good T2DM control is often difficult due to the required
lifestyle changes, including: modifying eating habits, main-
taining optimal body weight, exercising regularly and self-
monitoring of blood sugar [10]. Non-compliance with long
term management of T2DM may lead to serious negative
effects on health systems, such as compromised health
benefits and serious economic consequences in terms of
wasted time, money and uncured disease [11].
As a result of the chronic course of the disease, the de-
bilitation of complications and the complexities of treat-
ment plans, many T2DM patients manage their disease
through the use of complementary and alternative medi-
cine (CAM) therapies [10]. The US National Center for
CAM therapies divides CAM into four categories: (1)
Mind-body systems; (2) Manipulative and body-based
practices; (3) Energy Medicine; and (4) Biologically based
practices [12]. In this manuscript, CAM refers to biologic-
ally based practices including substances found in nature,
such as herbs, dietary supplements, multivitamin and min-
eral supplements, as well as prayers. Such therapies are
used for the prevention and treatment of diseases and are
meant to complement mainstream medicine by: “satisfying
a demand not met by orthodoxy or by diversifying the
conceptual frameworks of medicine” [13]. CAM therapies
are gaining public acceptance and are increasingly used
around the globe, especially among individuals with
chronic illnesses such as T2DM [14-16]. Patients may re-
sort to CAM use for a multitude of reasons including: dis-
satisfaction with conventional treatment, the adverse
effects experienced with drugs and the high cost of such
drugs [17-20]. Additional reasons include patients’ need
to have personal control over the course of their dis-
ease, as well as the perceived compatibility of CAM
therapies with patients’ values, spiritual/religious phil-
osophy and beliefs regarding the nature and the mean-
ing of death and illness [17,19-22].
However, despite the growing popularity of CAM use,
there is still insufficient evidence to draw conclusions
about the efficiency of many common CAM therapies,
including herbs and supplements for prevention and
management of diabetes [23]. While several comprehen-
sive reviews have found evidence on the effective use of
extracts of plants in the treatment of diabetes [24,25],
few studies reported significant side effects of CAM use
in T2DM [26].In the EMR, little is known about the prevalence of
use of CAM therapies in general and among diabetic
patients in particular. High rates of CAM use, extend-
ing from 25% to 85% of individuals with diabetes, were
reported in Turkey [27-29]. In Bahrain the prevalence
rate was also high among diabetic patients, estimated at
63%, whereas in Jordan it was noted to be 16.6% [4,30].
Notwithstanding the fact that Lebanon is a country
where CAM use is both prevalent and culturally ac-
cepted, there is no available data on the prevalence and
determinants of CAM use among Lebanese diabetic pa-
tients. Investigating the prevalence of CAM use, the
causes and modes for use, and patients disclosure of such
use is crucial since results could help protect the health of
patients, improve the patient-provider communication and
coordination, and help integrate CAM therapies into main-
stream medicine.
The aim of this study is to investigate the prevalence
and socio-demographic correlates of CAM use among
T2DM patients in Lebanon and to characterize the mode
of CAM use in this patient population, whether CAM was
used as complementary or alternative to mainstream
medicine. Such investigation aims at providing some es-
sential evidence that could guide decision making at the
system, institutional and individual levels.
Methods
A cross-sectional study assessing the prevalence, types,
modes and determinants of CAM use among Lebanese
T2DM patients was conducted between the months of
August 2010 and January 2011. The subjects were from
the two major referral centers in Beirut- a public hospital
and a private academic medical center. Both medical cen-
ters are accredited by the Lebanese Ministry of Health and
attract a large proportion of the patient population in the
Greater Beirut Area. Ethical approval for this study was
obtained from the Institutional Review Board (IRB) of the
Social and Behavioral Sciences at the American University
of Beirut, under protocol number NUT.FN.04.
Subjects and procedure
The pool of participants in this study included patients
older than 18 years of age of both genders who had
been diagnosed with T2DM for at least one year prior
to recruitment and who have returned to either of the
two hospitals for continuation of the treatment. For
sample size calculation, the following formula was used
[31]: n = Z21 ‐ α/2P(1 ‐ P)/e2.
Where
n = number to sample
Z2 = (1.96)2 for 95% confidence
P = “best guess” for prevalence
e =maximum tolerable error for the prevalence estimate
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(P), a 95% confidence interval (Z = 1.96) and a prevalence
estimate within 5% error margin (e), a sample of 344 adults
with T2DM was deemed appropriate for this study.
With the consent of target institutions and treating physi-
cians, all patients fitting the inclusion criteria were recruited
while waiting for their turn in the clinics waiting areas on
random days. The nurses in charge at the clinics introduced
the study to all eligible patients present in the waiting areas.
A nurse and a graduate student in Nutritional Sciences car-
ried out data collection. Both field workers had undergone
extensive training in questionnaire administration and
interviewing techniques and were clearly instructed and
reminded to avoid asking any leading questions that
could bias patients’ answers in any particular direction.
In addition, weekly meetings of the research team were held
to ensure the inter-rater reliability and the standardization
of data collection protocol. Each participant was interviewed
only once. Health care providers responsible for the treat-
ment of interviewed patients were not present during the
interviews. The participants were assured that any informa-
tion they reveal would remain confidential and would be
strictly used for research purposes only. Patients were not
paid to take part in the study and were informed that they
were free to decline answering any questions they were not
comfortable with. Signed consent forms were obtained from
all participating patients. Each interviewed patient was ad-
ministered a survey questionnaire, filled out through a face-
to-face interview. Interviews took an average of 20 minutes
to complete. To ensure a representative cross-sectional sam-
ple of patients from the two participating medical centers,
interviews were conducted on different days of the week
and at varying times.
Survey instrument
The survey instrument was divided into three sections:
socio-demographic characteristics, diabetes-related char-
acteristics and modes and experience of CAM use.
Socio-demographic data collected included: age, sex,
place of birth, marital status, educational level, employ-
ment status, health insurance and monthly income. The
second section of the questionnaire included questions
related to T2DM, such as: age at diagnosis, duration of
the disease, family history of T2DM, and presence of
T2DM complications. The last part of the questionnaire
focused on CAM use. This section included questions
about the type of CAM used, factors influencing the de-
cision to use CAM, the reasons for CAM use, experi-
ence of any side effect as a result of the CAM used, the
use of CAM as alternative or complementary to main
stream medicine, the disclosure of CAM use to treating
physicians and the reasons for not using CAM.
The content validity of the survey instrument was con-
firmed by an expert panel consisting of a physician, anutrition epidemiologist and a health management and
policy expert. Except for the question about the religious
beliefs of the patients, all of the questions included in the
survey instrument were deemed appropriate. Given the
political tension in the country among various religious
parties, the panel decided to drop this question despite the
suggested influence of such beliefs on the use of CAM
modalities. The original version of the questionnaire was
written in English and subsequently translated to Arabic
(since the majority of patients spoke Arabic). The translated
Arabic version was back translated by a professional trans-
lator to ensure the parallel-form reliability of the question-
naire. The original and the back translated versions were
reviewed for consistency in meaning by two bilingual ex-
perts. A pilot study was conducted with 15 selected diabetic
patients to ensure that the target population understood
the questions and that the answers yielded the required
data. The findings of the pilot study were included in the
analysis of the data for the present study.
Statistical analysis
The data was checked for completeness, and responses
were coded and entered into the Statistical Package for the
Social Sciences (SPSS) software version 18 for Windows,
which was later used for statistical analyses [32]. Frequen-
cies and percentages were used to assess the prevalence,
types, mode and patterns of CAM. CAM use, the main out-
come in this study, was defined as using CAM at least
once since diagnosis with T2DM. Chi-square and inde-
pendent t-tests were used to chart comparisons of cat-
egorical and continuous variables between users and
non-users of CAM. Univariate and multivariate logistic
regression analyses were applied to determine which
factors are associated with the use of CAM. In the re-
gression model, CAM use was used as the dependent
variable. In addition to age and sex, characteristics that
showed statistical significance in the univariate analysis
were included in the multivariate model as independent
variables. Odds ratios and their respective 95% confi-
dence intervals were calculated. A p-value of 0.05 was
used to determine statistical significance.
Results
Out of 352 T2DM patients invited to participate in this
study, a total of 333 completed the survey questionnaire
(response rate 94.6%). The main reasons for refusal to
participate were lack of time or disinterest in the study
objectives. Table 1 displays the socio-demographic and
disease-related characteristics of the overall study popu-
lation including CAM users and CAM non-users. Com-
parable proportions of patients were recruited from the
private academic medical center and the public hospital
(46.2% vs 53.8%). Patients’ average age was 60.29 ±
11.89 years, with 184 (55.3%) males and 238 (71.5%)
Table 1 Socio-demographic and disease-related characteristics of the study population (n = 333) and their association
with CAM use
Characteristic Overall (n = 333) CAM users (n = 127) CAM non-users (n = 206) OR (95% CI)
Site/Medical Center (n = 333)
AUB-MC 154(46.2) 50(32.5) 104(67.5) 1
RHUH 179(53.8) 77(43.0) 102(57.0) 1.57(1.00-2.46)
Age (years) (mean ± SD) (n = 333) 60.20 ± 11.89 58.52 ± 10.98 61.20 ± 12.33 0.98(0.96-1.00)
Sex (n = 333)
Male 184(55.3) 76(41.3) 108(58.7) 1
Female 149(44.7) 51(34.2) 98(65.8) 0.74(0.47-1.16)
Place of birth (n = 333)
Village 95(28.5) 42(44.2) 53(55.8) 1
Town-city 238(71.5) 85(35.7) 153(64.3) 0.70(0.43-1.14)
Marital status (n = 333)
Not married 95(28.5) 26(27.4) 69(72.6) 1
Married 238(71.5) 101(42.4) 137(57.6) 1.96(1.16-3.29)
Education (n = 331)
Illiterate 39(11.8) 15(38.5) 24(61.5) 1
Elementary school 119(36.0) 53(44.5) 66(55.5) 1.28(0.613-2.69)
High school 87(26.3) 31(35.6) 56(64.4) 0.89(0.41-1.93)
University level 86(26.0) 26(30.2) 60(69.8) 0.69(0.31-1.53)
Employment (n = 333)
Not employed 221(66.4) 83(37.6) 138(62.4) 1
Employed 112(33.6) 44(39.3) 68(60.7) 1.08(0.67-1.72)
Presence of health insurance (n = 332)
Uninsured 187(56.3) 79(42.2) 108(57.8) 1
Insured 145(43.7) 48(33.1) 97(66.9) 0.68(0.43-1.06)
Monthly income (n = 286)
500-1000$ 59(20.6) 32(54.2) 27(45.8) 1
<500$ 117(40.9) 41(35.0) 76(65.0) 0.45(0.24-0.86)
>1000$ 110(38.5) 38(34.5) 72(65.5) 0.44(0.23-0.85)
Diabetes related characteristics
Age at diagnosis of T2DM (years) (mean ± SD) (n = 333) 49.09 ± 12.27 46.28 ± 10.546 50.83 ± 12.940 0.97(0.95-1.01)
Duration of T2DM (years) (mean ± SD) (n = 333)
1-2 years 59(17.7) 12(20.3) 47(79.7) 1
3-5 years 52(15.6) 22(42.3) 30(57.7) 2.87(1.24-6.65)
6-10 years 79(23.7) 34(43.0) 45(57.0) 2.96(1.36-6.42)
11-15 years 63(18.9) 22(34.9) 41(65.1) 2.10(0.93-4.76)
>15 years 80(24.0) 37(46.3) 43(53.8) 3.37(1.56-7.29)
Family history of diabetes mellitus (n = 333)
No 151(45.3) 53(35.1) 98(64.9) 1
Yes 182(54.7) 74(40.7) 108(59.3) 1.25(1.10-1.38)
Presence of diabetes complications (n = 333)
No 138(41.4%) 44(31.9) 94(68.1) 1
Yes 195(58.6%) 83(42.6) 112(57.4) 1.58(1.003-2.50)
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Table 2 Correlates of CAM use using multivariate logistic
regression
Characteristic OR (95% CI)
Site/Medical Center (n = 333)
AUB-MC 1
RHUH 1.44(0.60-3.44)
Age (years) (mean ± SD) (n = 333) 0.98(0.96-1.004)
Sex (n = 333)
Male 1
Female 0.83(0.44-1.59)
Marital status (n = 333)
Not married 1
Married 1.95(1.02-3.84)















Presence of diabetes complications (n = 333)
No 1
Yes 1.71(1.3-3.51)
Family history of diabetes mellitus (n = 333)
No 1
Yes 1.15(1.02-1.30)
Naja et al. BMC Complementary and Alternative Medicine 2014, 14:185 Page 5 of 11
http://www.biomedcentral.com/1472-6882/14/185married. The sample population comprised subjects from
all levels of education ranging from illiterate (11.8%) to
university level (26%). A considerable proportion of pa-
tients (56.3%) reported no health insurance coverage and
about 41% reported a monthly income less than 500$. The
average age at diagnosis was 49.1 ± 12.27 years. More than
half of the study population reported a positive family his-
tory of T2DM (54.7%) and the presence of complications
as a result of their T2DM (58.6%). Compared to the pri-
vate academic medical center, patients attending clinics in
the public hospital were more likely to use CAM (OR:
1.57; CI: 1.002-2.46). Using bivariate logistic regression,
factors that were associated with CAM use in the study
population included site of recruitment, marital status,
monthly income, duration of T2DM, family history of the
disease, as well as presence of T2DM complications. Com-
pared to not married, married patients had twice the odds
of using CAM (OR: 1.96; CI: 1.16-3.29). Patients reporting
an income less than 500$ or more than 1000$ had signifi-
cantly lower odds of using CAM as compared to those
reporting middle income range (500-100$) (OR: 0.45; CI:
0.24-0.86 and OR: 0.44; CI: 0.23-0.85 respectively). The
longer the duration of diabetes the higher were the odds
of CAM use with patients diagnosed for a period over
15 years having the highest odds (OR:3.37; CI: 1.56-7.29).
“Having a positive family history of diabetes” and “pres-
ence of diabetes complications” were both associated with
higher odds of CAM use (OR: 1.25; CI: 1.10-1.38 and OR:
1.58; CI: 1.003-2.50 respectively).
A multivariate logistic regression model was used to
examine the correlates of CAM use in the study popula-
tion (Table 2). Variables were put in the model in order of
strength of their association with CAM use as per the bi-
variate analysis. The effect of each variable on the model
was assessed and the variable was kept if it significantly
contributed to a better fit of the model. The final model
included the following variables: site of recruitment, age,
sex, marital status, education monthly income, duration of
T2DM, presence of diabetes complications, and family
history of diabetes. The results of the multivariate model
showed that CAM use was significantly associated with a
“married” status (OR 1.95; 95% CI: 1.02-3.84), a longer
duration of T2DM (OR 2.99; 95% CI: 1.23-7.28 for pa-
tients diagnosed with T2DM longer than 15 years as com-
pared to 1–2 years), the presence of disease complications
(OR: 1.71; 95% CI: 1.3-3.51), and a positive family history
of the disease (OR: 1.15; 95% CI: 1.02-1.30).
Table 3 describes the prevalence, modes and characteris-
tics of CAM use among study participants. The prevalence
of CAM use in the study population was 38%, 95% CI
(33.1-43.5). Seventy patients (21%) have used CAM at
least once during the last 12 months. The majority of
CAM users (66.1%) reported that their choice of the CAM
therapy was influenced by their friends while only 7.1%were guided by health practitioners. Trying for the sake of
experimentation and believing in the advantages of CAM
practices were the most commonly cited reasons for CAM
use (63.8% and 41.7% respectively). Forty five patients
(35.4%) described the CAM they have used as “not all use-
ful”; thirteen patients (10.2%) reported experiencing side
effects due to CAM they used, and almost one in two
CAM users (46.5%) said that they will not use it again.
Eighteen patients (20.9%) used CAM as alternative to the
mainstream medicine while 79.1% used the CAM on com-
plementary basis. The comparison of socio-demographic
and disease related characteristics between patients who
used CAM as complementary and those who used it as
Table 3 Prevalence, modes and characteristics of CAM
use among patients with T2D (n = 333)
Prevalence and types of CAM used among diabetic patients n (%)
Used CAM in the previous year
Yes 70(21)
No 263(79)
Used CAM since diagnosis
Yes 127(38.1)
No 206(61.9)







Reasons of CAM use*
Trying CAM for the sake of experiment 81(63.8)
Belief in advantages of CAM practices 53(41.7)
Looking for another solution 23(18.1)
Lost hope with conventional therapy 6(4.7)
CAM is accessible and available 1(0.8)
What was your expectation when you were using CAM
Prevent progression of diabetes 34(26.8)
No expectations 29(22.8)
Complete cure of disease 28(22.0)
Lowering blood glucose level 24(19.0)
Weight loss 3(2.4)
Better health status 2(1.6)
Other** 6(4.7)
Feeling after CAM use*
Feeling of strengthening of body 60(47.2)
Feeling of no change 58(45.7)
Feeling of disappearance of several symptoms 40(31.5)
Feeling of being in good psychological condition 31(24.4)
Feeling physically worse 7(5.5)
Feeling rise of several symptoms 6(4.7)
Not decided 2(1.6)
Feeling of being in bad psychological condition 1(0.8)
Fear of the product and its effect 1(0.8)
Improvement of sexual life 1(0.8)
How do you assess the usefulness of CAM?
No useful at all 45(35.4)
Very useful 30(23.6)
Not sure/unable to assess 28(22.0)
Of limited usefulness 24(18.9)
Table 3 Prevalence, modes and characteristics of CAM
use among patients with T2D (n = 333) (Continued)












Was your use complementary or alternative (n = 86)?
Complementary 68(79.1)
Alternative 18(20.9)
Did you consult a doctor before using CAM (n = 130)?
Yes 9(6.9)
No 121(93.1)
CAM related characteristics among diabetic
non-users (n = 206)†
Reasons for not using CAM*
Do not believe in it 133(64.6)
The doctor did not prescribe it 58(28.1)
Afraid of the side effects 47(22.8)
Never heard of it 15(7.3)
Additional expenses and useless 14(6.8)
Do no need it 12(5.8)
Mainstream medicine is the best 4(1.9)
Not interested 4(1.9)
CAM is not evidence based 3(1.4)
No one advised its use 3(1.4)
Other*** 3 (1.4)
Would you consider using CAM in the future
Yes 37(18.0)
No 169(82.0)
*More than one answer was applicable.
Other **: *Other expectations when you were using CAM: Getting rid from
sorcery spell (n = 1), Cure from osteoarthritis (n = 1), Pain relief (n = 2), Stop
using medications (n = 1), feeling psychologically better (n = 1).
Other ***There is no definite and ultimate cure for T2DM, Negligence, Old way
of treating diseases.
†These questions were asked only to CAM non users.
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ences except for health insurance whereby a significantly
higher proportion of alternative use was observed among
un-insured compared to insured patients (27.3% vs. 6%,
Chi-Square: 19.7; p < 0.05 respectively) (data not shown).
Figure 1 Distribution (%) of various CAM types as used by the study population*.
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ity they were using with a physician.
Folk food and herbal remedies were the most com-
mon type of CAM used (81%) among study participants
(Figure 1). Other CAM modalities used by the study
population were natural health products (28%), spiritual
healing (11.8%), and vitamins and minerals (3%) (Figure 1).
Folk food and herbal remedies included functional foods
and herbal infusions that belonged to the Lebanese folk
methods of healing and were available in traditional herbal
stores. Natural health products referred to prepackaged
natural products that presented a health claim. Most of
the Natural health products used by the study population
were produced locally (90%) while the rest were imported.
Spiritual healing included mainly prayers and vows. In the
category of “vitamins and minerals”, multivitamins prepa-
rations and vitamin C were reported.
Discussion
The study revealed that 38.1% of surveyed patients attend-
ing diabetes clinics in Beirut reported at least one incidence
of using CAM therapies since diagnosis with T2DM. Other
studies have reported a varying range of CAM use rates
among T2DM patients depending on the country or geo-
graphic region. Compared to our findings, studies from
Europe and North America yielded lower prevalence esti-
mates. For example, among diabetes patients attending
outpatient’s clinics in the UK, 17% reported the use of
CAM [33]. In Canada, 25% of patients with diabetes used a
type of CAM therapy [34]. Conversely, prevalence esti-
mates of CAM use among T2DM patients were higher in
South America and Asia as compared to our findings. For
instance, the prevalence of CAM use among T2DM pa-
tients in Mexico was estimated at 62% [35]. In Asia, the
prevalence estimates of 61%, 67.7% and 65% were ob-
served in Taiwan, India and Korea respectively [36,37]. In
Malaysia, a cross sectional study investigating the use ofCAM among T2DM in the primary care setting found a
prevalence of use of 62.5%, , similar to other rates ob-
served in Asia [38]. In the Middle East region, studies
among Jordanian and Palestinian patients found preva-
lence of CAM use of 16.6% and 51.9% respectively[4,39].
These observed variations in CAM use by geographic re-
gion could be in part attributed to differences in socio-
cultural perceptions of CAM use and to disparities in the
availability and access to conventional medicine. In
addition, differences in study designs and definitions of
CAM might have also contributed to the varying preva-
lence estimates of CAM use by T2DM patients in these
countries [7].
Study findings revealed that folk foods and herbs were
the most commonly used CAM followed by natural
health products, spiritual healing and vitamins and min-
erals supplements. Lebanon is a small country in a re-
gion earlier referred to as “Bilad al Sham” – the Levant.
This region was endowed with a high floral diversity that
has for long constituted a basis for health care with very
few species imported from outside it [40]. Lebanese herbal-
ists, similar to other Arab herbalists in the region, have
managed to maintain relics of the traditions alive into the
twenty-first century and they still include, in their repertoire
of medicinal use, hundreds of plant species even though
very few of these plants have had their medicinal properties
investigated using contemporary evidence based medicine
[41,42]. Our results showed that, the cultural value of herbal
treatments remains part of the collective memory of the
people of the region despite its marginalization and decline.
In addition, ease of accessibility and lower cost of folk prod-
ucts may have contributed to the observed wide spread use
of the food and herbal remedies in our study population.
Furthermore, in this study, spiritual healing was used by
a significant proportion of T2DM patients (12%). Examples
of practices reported included prayers, lighting candles in
churches and consulting with religious authorities. It is
Naja et al. BMC Complementary and Alternative Medicine 2014, 14:185 Page 8 of 11
http://www.biomedcentral.com/1472-6882/14/185important to note that, in this study, spiritual healing, al-
though it undeniably included the action of praying, was
distinct from private, devotional communication (which
may include daily petitions for health, blessings, forgiveness,
and grace). Inexpensive and easy to use, these therapies
have the advantage of being safe [43] with this type of
CAM, though health benefits are not guaranteed; there ap-
pears to be positive association between religiousness/spir-
ituality, and higher wellbeing and positive effect, as well as
a negative association with depressive and anxiety symp-
toms [44].
Study findings indicated that only 7% of T2DM patients
were referred to use CAM by their health practitioners,
compared to two thirds of CAM users being referred or
encouraged to use CAM by a friend. In addition, only
6.9% informed their physician of such use, despite the fact
that patient were recruited from physician’s clinics. Other
studies revealed a similar or even lower pattern of report-
ing [35,36,45-48]. These findings suggest that health care
practitioners played a marginal role in regards to their pa-
tients’ use of CAM therapies and that they remain largely
blinded to their patients’ use of CAM despite the fact that
some patients are using CAM on an alternative basis to
current treatment. Such a finding is disconcerting since a
considerable proportion of CAM users either found CAM
therapies ineffective (35.4%) or experienced at least one
side effect (10.2%).
The fact that T2DM patients attending public hospitals
(usually patients belonging to lower socioeconomic status-
SES) and those reporting no health insurance coverage
had a higher probability of using CAM therapies reflect a
socio-economic discrepancy in regards to CAM use
among surveyed patients. Furthermore, study findings in-
dicated that the propensity of using CAM on an alterna-
tive basis was associated with lack of insurance. Those
patients might have been encouraged to use CAM due to
the low cost of such therapies as compared to conven-
tional ones. Similar to our study, use of complementary
medication by patients with T2DM in Mexico was corre-
lated with lack of insurance [49]. However, the literature
on the relationship between the use of CAM and SES is
inconclusive, with a clear geographical discrepancy. For
example, a higher SES was correlated with a greater CAM
usage in most regions of North America and Western Eur-
ope. In contrast, lower SES was associated with CAM
usage in countries like Turkey and Hawaii [19]. While, the
findings of our study in regards relationship between SES
and CAM use are more in synchrony with countries closer
to Lebanon (e.g. Turkey), future studies are needed to
confirm whether patients are more prone to use CAM as
a cheaper alternative to conventional therapies or perhaps
due to other environmental and cultural reasons.
In addition to public hospital patients and those with no
health insurance, attention should be dedicated to CAMuse patterns of patients with longer duration of T2DM and
to those reporting the presence of diabetes complications.
These patients may resort to using CAM therapies on an
alternative or complementary basis due to their fatigue and
despair with conventional therapies, to save costs or to try
something new Other studies on CAM use among T2DM
have also found similar findings [17,19,20,22]. Furthermore,
patients seek more alternative therapies because these ther-
apies seem less authoritarian and more empowering and as
offering them more personal autonomy [50].
A number of shortcomings in this study are worth men-
tioning. First, and most importantly, the data collection in-
volved patients waiting in the clinics of two hospitals.
Although patients were asked to report their habits and
opinions and were assured the confidentiality and privacy
of their responses, it cannot be ascertained that patients
did not experience the social desirability bias, potentially
altering their answers to satisfy their health care providers.
Second, and related to the aforementioned point, the ex-
ternal validity of the findings of the current study might
only be applicable to T2DM patients attending diabetic
clinics. The prevalence and patterns of CAM use in pa-
tients that are not regularly being followed up by physi-
cians and those with uncontrolled T2DM might need to
be established in a different study design. Third, recall bias
might have been experienced by some patients especially
that many of them were old and were asked about their
recent and life time use of CAM therapies. Finally, al-
though data collection involved well-trained interviewers,
it cannot be assured that patients were able to compre-
hend all the questions in the survey instrument.
Policy and practice recommendations
The strength of the current study is in it being the first of
its kind in Lebanon to examine the prevalence, socio-
demographic correlates and mode of CAM use among
T2DM in Lebanon. The scale of the study may not reflect
the national scene and the need for additional studies of a
larger scale is clearly noted. Nevertheless, the attention of
concerned stakeholders are attracted to a number of po-
tential policy and practice implications that deem their at-
tention, Such stakeholders include the Ministry of Public
Health (MOPH), Syndicates and Orders, medical, nursing
and health related schools and research institutions.
Prompted by the findings of this study, the Ministry of
Public Health (MOPH) could act on three fronts: First,
the concerns in regards to the unsafe use of CAM ther-
apies by T2DM patients and associated side effects need
to be thoroughly investigated and regulatory tools need
to be utilized in order to protect the consumers. Such tools
may range from educating consumers on safe use to the
withdrawal of unsafe drugs from the market [51,52]. Sec-
ond, the study prompts the MOPH on the need to exam-
ine the equitable access by all T2DM patients, irrespective
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and affordability of diabetes care and therapies [53,54].
This could be done through restructuring financing
mechanisms, particularly for essential medicines used
by T2DM patients, in order to reduce out-of-pocket ex-
penditures [53]. Other potential policy options include
prioritized budgeting, access to and promotion of gen-
eric medicines, price regulation, improved procurement
efficiency [55,56]. Third, to build on the findings of this
study and to contextualize and enhance the validity of the
recommendations, the MOPH could initiate a national dia-
logue bringing together all stakeholders (orders, syndicates,
medical schools, nursing colleges, media, drug importers,
consumer protection agencies, etc.) to discuss enhancing
the safe use of CAM therapies with the public in general
and diabetic patients in particular [51,57].
The findings of this study also encourage medical syndi-
cates and orders to play examine their role in enhancing
both the healthcare providers’, as well as the consumers’
awareness on the safe use of CAM therapies in general and
those targeting diabetic patients in particular. Practicing
clinicians, nurses, pharmacists and dieticians may need to
enhance their awareness not only on available CAM ther-
apies for diabetic patients and their associated advantages
and disadvantages, but also on effective communication
with their patients in order to encourage them to acknow-
ledge and discuss safe use of CAM therapies with their
providers [22,51,52]. Examples of such programs include
training programs for patient-centered care and communi-
cation skills, initiatives to overcome physicians’ attitudinal
barriers toward CAM, professional development programs
aiming at educating practicing professionals on the safe
and effective use of CAM products [51,58-60]. Linking
such programs to continuing education credits could en-
courage providers to enhance their knowledge and skills
about the topic. As the study revealed, particular attention
ought to be dedicated to patients attending public hospitals
and those that do not have insurance coverage. Syndicates
and orders could also join efforts to enhance the public
awareness on the safe consumption of CAM therapies by
conducting awareness campaigns, annual inventories of ap-
proved and safe products published both in print and elec-
tronically or by assigning a hotline to offer consumers
information on safe use of CAM products [51].
While continuing education programs would potentially
enhance the knowledge and skills of current practicing pro-
fessionals on the safe use of CAM therapies, the examin-
ation of medical, nursing and other health related curricula
would ensure the future graduating health providers are
well educated to discuss the safe use of CAM therapy op-
tions with their patients in general and diabetic ones in
particular [11,51,52,58,61]. Findings of this study call on
medical, nursing and other health related schools to re-
examine their curricula integrating CAM education andthe means to incorporate such popular therapies with con-
ventional treatments.
Research institutions could also play an important role
in investigating the enablers and barriers for safe CAM
use among diabetics and the means to enhance this safety.
Although this study was able to shed light on a number of
important facts and figures related to the prevalence and
modes of CAM use among T2DM patients, it is limited in
terms of the external validity of its findings and it also had
left a number of important unanswered questions. For ex-
ample, future research studies could build on the findings
of this study by examining T2DM patients’ prevalence and
determinants of CAM use at the national and regional
levels. Studies could also examine the underlying causes
for the lack of patients’ reporting of CAM use to their care
providers and the strategies to enhance transparency be-
tween patients and providers. The regulatory mechanisms
and policy instruments that the government could utilize
to regulate the CAM market, taking into consideration the
Lebanese health care context, could also be examined.
Conclusion
The use of CAM therapies among T2DM patients in
Lebanon is prevalent. Decision makers and care providers
are encouraged to consider the potential risks and benefits
of CAM therapies, especially in the light of the significant
proportion of patients who were found to use CAM on an
alternative basis. Particular attention must be dedicated to
educating T2DM patients, especially those with a family
history of diabetes and those who had the disease for a
long period, about the safe use of CAM and the import-
ance to disclose the CAM use to their treating physician.
A concerted effort by the government, orders and syndi-
cates, medical, nursing and health schools and educational
institutions is required to enhance the safe use of CAM
therapies by T2DM patients and to help integrate CAM
therapies into the conventional treatment of diabetic pa-
tients. A study of a national scale validating the findings of
this manuscript is highly recommended.
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